CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.

Amgen Inc Thousand Oaks California USA

Department of Haematology Princess Alexandra Hospital and University of Queensland Medical School Brisbane QLD Australia

Department of Haematooncology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Internal Medicine Division of Hematology Ondokuz Mayıs University Faculty of Medicine Samsun Turkey

Department of Oncology Hematology and BMT University Medical Center of Hamburg Eppendorf Hamburg Germany

Division of Hematology Sylvester Comprehensive Cancer Center Miami Florida USA

Hospital Clínic IDIBAPS Barcelona Spain

Memorial Sloan Kettering Cancer Center New York New York USA

Parexel Chengdu China

Service d'hématologie Clinique Centre Hospitalier Universitaire de Nantes Nantes France

Yonsei University College of Medicine Severance Hospital Seoul Republic of South Korea

000      

00000naa a2200000 a 4500

001      

bmc22024524

003      

CZ-PrNML

005      

20221031100109.0

007      

ta

008      

221017s2022 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1111/bjh.18233 $2 doi

035    __

$a (PubMed)35608261

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Landgren, Ola $u Division of Hematology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA $1 https://orcid.org/0000000164854839

245    10

$a Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study / $c O. Landgren, K. Weisel, L. Rosinol, C. Touzeau, M. Turgut, R. Hajek, P. Mollee, JS. Kim, N. Shu, X. Hu, C. Li, SZ. Usmani

520    9_

$a CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.

650    _2

$a dospělí $7 D000328

650    12

$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971

650    _2

$a cytogenetické vyšetření $7 D020732

650    _2

$a dexamethason $x terapeutické užití $7 D003907

650    _2

$a lidé $7 D006801

650    12

$a mnohočetný myelom $x farmakoterapie $x genetika $7 D009101

650    _2

$a prognóza $7 D011379

650    _2

$a výsledek terapie $7 D016896

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a Research Support, N.I.H., Extramural $7 D052061

700    1_

$a Weisel, Katja $u Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

700    1_

$a Rosinol, Laura $u Hospital Clínic, IDIBAPS, Barcelona, Spain $1 https://orcid.org/0000000225349239

700    1_

$a Touzeau, Cyrille $u Service d'hématologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France $1 https://orcid.org/0000000302752575

700    1_

$a Turgut, Mehmet $u Department of Internal Medicine, Division of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey

700    1_

$a Hajek, Roman $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267

700    1_

$a Mollee, Peter $u Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical School, Brisbane, QLD, Australia

700    1_

$a Kim, Jin Seok $u Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of South Korea $1 https://orcid.org/0000000189868436

700    1_

$a Shu, Natalie $u Parexel, Chengdu, China

700    1_

$a Hu, Xuguang $u Amgen Inc., Thousand Oaks, California, USA

700    1_

$a Li, Chuang $u Amgen Inc., Thousand Oaks, California, USA

700    1_

$a Usmani, Saad Z $u Memorial Sloan Kettering Cancer Center, New York, New York, USA

773    0_

$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 198, č. 6 (2022), s. 988-993

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35608261 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20221017 $b ABA008

991    __

$a 20221031100107 $b ABA008

999    __

$a ok $b bmc $g 1854316 $s 1175814

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 198 $c 6 $d 988-993 $e 20220524 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374

GRA    __

$a P30 CA240139 $p NCI NIH HHS $2 United States

LZP    __

$a Pubmed-20221017